Effects of high glucose and high insulin concentrations on osteoblast function in vitro

Cell and Tissue Research

Volumn 358, Issue 1, 2014, Pages 249-256

  Cunha, Juliana S ^a   Ferreira, Vanessa M ^a   Maquigussa, Edgar ^a   Naves, Marcelo A ^a   Boim, Mirian A ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Diabetes mellitus; Glucose; Insulin; Mineralization; Mouse cell line; Osteoblast

Indexed keywords

ALKALINE PHOSPHATASE; COLLAGEN TYPE 1; GLUCOSE; GLUCOSE TRANSPORTER 1; INSULIN; MANNITOL; MESSENGER RNA; OSMOTIC AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE RECEPTOR; ANTIDIABETIC AGENT; SWEETENING AGENT;

ANIMAL CELL; ARTICLE; BONE ATROPHY; BONE DISEASE; BONE FRAGILITY; BONE MINERALIZATION; BONE REMODELING; CONTROLLED STUDY; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HYPERGLYCEMIA; HYPEROSMOLARITY; IN VITRO STUDY; INSULIN BLOOD LEVEL; MOUSE; NONHUMAN; OSTEOBLAST; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; DRUG EFFECTS; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; METABOLISM; OSTEOLYSIS; PATHOLOGY; TRANSFORMED CELL LINE;

ANIMALS; BONE RESORPTION; CELL LINE, TRANSFORMED; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GLUCOSE; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MICE; OSTEOBLASTS; SWEETENING AGENTS;

EID: 84919847409     PISSN: 0302766X     EISSN: 14320878     Source Type: Journal    
DOI: 10.1007/s00441-014-1913-x     Document Type: Article

References (40)

1. Andress DL (2008) Adynamic bone in patients with chronic kidney disease. Kidney Int 73:1345–1354
2. Balint E, Szabo P, Marshall CF, Sprague SM (2001) Glucose-induced inhibition of in vitro bone mineralization. Bone 28:21–28
3. Botolin S, McCabe LR (2006) Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. J Cell Biochem 99:411–424
4. Botushanov NP, Orbetzova MM (2009) Bone mineral density and fracture risk in patients with type 1 and type 2 diabetes mellitus. Folia Med (Plovdiv) 51:12–17
5. Brancaccio D, Cozzolino M (2011) CKD-MBD: an endless story. J Nephrol 24 (Suppl 18):S42–S48
6. Christenson RH (1997) Biochemical markers of bone metabolism: an overview. Clin Biochem 30:573–593
7. Clarke B (2008) Normal bone anatomy and physiology. Clin J Am Soc Nephrol 3 (Suppl 3):S131–S139
8. Covic A, Apetrii M (2011) Vitamin D receptor activation: clinical outcomes. Contrib Nephrol 171:166–171
9. Ensrud KE, Lui LY, Taylor BC, Ishani A, Shlipak MG et al (2007) Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med 167:133–139
10. Farhat GN, Strotmeyer ES, Newman AB, Sutton-Tyrrell K, Bauer DC et al (2006) Volumetric and areal bone mineral density measures are associated with cardiovascular disease in older men and women: the health, aging, and body composition study. Calcif Tissue Int 79:102–111
11. Fried LF, Shlipak MG, Stehman-Breen C, Mittalhenkle A, Seliger S et al (2006) Kidney function predicts the rate of bone loss in older individuals: the Cardiovascular Health Study. J Gerontol A Biol Sci Med Sci 61:743–748
12. Garcia-Hernandez A, Arzate H, Gil-Chavarria I, Rojo R, Moreno-Fierros L (2012) High glucose concentrations alter the biomineralization process in human osteoblastic cells. Bone 50:276–288
13. Grigoropoulou P, Eleftheriadou I, Zoupas C, Tentolouris N (2011) The role of the osteoprotegerin/RANKL/RANK system in diabetic vascular disease. Curr Med Chem 18:4813–4819
14. Isidro ML, Ruano B (2010) Bone disease in diabetes. Curr Diabetes Rev 6:144–155
15. Janghorbani M, Van Dam RM, Willett WC, Hu FB (2007) Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 166:495–505
16. Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE et al (2003) Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 149:39–42
17. Kumagai AK (1999) Glucose transport in brain and retina: implications in the management and complications of diabetes. Diabetes Metab Res Rev 15:261–273
18. Leslie WD, Rubin MR, Schwartz AV, Kanis JA (2012) Type 2 diabetes and bone. J Bone Miner Res 27:2231–2237
19. Lorenzo Sellares V, Torregrosa V (2008) Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis). Nefrologia 28 (Suppl 3):67–78
20. Lozano D, de Castro LF, Dapia S, Andrade-Zapata I, Manzarbeitia F et al (2009) Role of parathyroid hormone-related protein in the decreased osteoblast function in diabetes related osteopenia. Endocrinology 150:2027–2035
21. Luppen CA, Smith E, Spevak L, Boskey AL, Frenkel B (2003) Bone morphogenetic protein-2 restores mineralization in glucocorticoid-inhibited MC3T3-E1 osteoblast cultures. J Bone Miner Res 18:1186–1197
22. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N et al (1998) Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247:610–615
23. Montagnani A, Gonnelli S, Alessandri M, Nuti R (2011) Osteoporosis and risk of fracture in patients with diabetes: an update. Aging Clin Exp Res 23:84–90
24. Moorthi RN, Moe SM (2011) CKD-mineral and bone disorder: core curriculum 2011. Am J Kidney Dis 58:1022–1036
25. Moseley KF (2012) Type 2 diabetes and bone fractures. Curr Opin Endocrinol Diabetes Obes 19:128–135
26. Nyman JS, Even JL, Jo CH, Herbert EG, Murry MR et al (2010) Increasing duration of type 1 diabetes perturbs the strength-structure relationship and increases brittleness of bone. Bone 48:733–740
27. Olesen P, Ledet T, Rasmussen LM (2005) Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia 48:561–568
28. Perez-Castrillon JL, De Luis D, Martin-Escudero JC, Asensio T, del Amo R et al (2004) Non-insulin-dependent diabetes, bone mineral density, and cardiovascular risk factors. J Diabetes Complicat 18:317–321
29. Picton ML, Moore PR, Mawer EB, Houghton D, Freemont AJ et al (2000) Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int 58:1440–1449
30. Rakic V, Davis WA, Chubb SA, Islam FM, Prince RL et al (2006) Bone mineral density and its determinants in diabetes: the Fremantle Diabetes Study. Diabetologia 49:863–871
31. Sardone LD, Renlund R, Willett TL, Fantus IG, Grynpas MD (2011) Effect of rosiglitazone on bone quality in a rat model of insulin resistance and osteoporosis. Diabetes 60:3271–3278
32. Simpson IA, Carruthers A, Vannucci SJ (2007) Supply and demand in cerebral energy metabolism: the role of nutrient transporters. J Cereb Blood Flow Metab 27:1766–1791
33. Terkeltaub RA (2001) Inorganic pyrophosphate generation and disposition in pathophysiology. Am J Physiol Cell Physiol 281:C1–C11
34. Thomas DM, Maher F, Rogers SD, Best JD (1996) Expression and regulation by insulin of GLUT 3 in UMR 106-01, a clonal rat osteosarcoma cell line. Biochem Biophys Res Commun 218:789–793
35. Wittrant Y, Gorin Y, Woodruff K, Horn D, Abboud HE et al (2008) High d(+)glucose concentration inhibits RANKL-induced osteoclastogenesis. Bone 42:1122–1130
36. Wu YY, Yu T, Zhang XH, Liu YS, Li F et al (2012) 1,25(OH)2D3 inhibits the deleterious effects induced by high glucose on osteoblasts through undercarboxylated osteocalcin and insulin signaling. J Steroid Biochem Mol Biol 132:112–119
37. Xiang GD, Pu JH, Zhao LS, Sun HL, Hou J et al (2009) Association between plasma osteoprotegerin concentrations and urinary albumin excretion in Type 2 diabetes. Diabet Med 26:397–403
38. Yan W, Li X (2013) Impact of diabetes and its treatments on skeletal diseases. Front Med 7:81–90
39. Yuan LQ, Zhu JH, Wang HW, Liang QH, Xie H et al (2011) RANKL is a downstream mediator for insulin-induced osteoblastic differentiation of vascular smooth muscle cells. PLoS One 6:e29037
40. Zoidis E, Ghirlanda-Keller C, Schmid C (2011) Stimulation of glucose transport in osteoblastic cells by parathyroid hormone and insulin-like growth factor I. Mol Cell Biochem 348:33–42